Search

STALEVO 150 MG / 37.5 MG / 200 MG, Comprimé pelliculé (Retiré du marché)

Details

--- Description
Pack Boîte de 100
Strength (Dosage) 150 MG / 37.5 MG / 200 MG
Laboratory NOVARTIS PHARMA MAROC
Ingredients Lévodopa | Entacapone | Carbidopa
Therapeutic class Lévodopa, inhibiteur de la décarboxylase et inhibiteur de la COMT
ATC code N04BA03
PPH $81.20
PPV $111.30
Refundable Yes
Refund base $111.30
Refund rate $0.00
Table A
Marketing status Commercialized
Type Medication
Uses Stalevo est destiné au traitement des patients adultes atteints de la maladie de Parkinson et présentant des symptômes de fluctuations motrices (appelés de fin de dose ou symptômes on-off) qui ne peuvent être stabilisées avec l'association lévodopa/inhibiteur de la dopa décarboxylase.
Warnings
Dosage
Avoid
Side effects
Interactions

Medications with one or more of the ingredients above


Medications under one or more of the therapeutic classes above


Medications from the same laboratory


Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.